您的位置: 首页 > 农业专利 > 详情页

ПРИМЕНЕНИЕ МИМЕОТОПОВ АЛЬФА-СИНУКЛЕИНОВЫХ ЭПИТОПОВ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С ТЕЛЬЦАМИ ЛЕВИ
专利权人:
АФФИРИС АГ (AT)
发明人:
МАНДЛЕР Маркус (AT),ВЕНИНГЕР Харальд (AT),САНТИК Радмила (AT),ЛАХСНИГ Кристиан (AT)
申请号:
RU2012110582/15
公开号:
RU2012110582A
申请日:
2010.08.20
申请国别(地区):
RU
年份:
2013
代理人:
摘要:
1. A composition comprising at least one peptide or polypeptide comprising an amino acid posledovatelnostgde X b is any amino acid residue Hpredstavlyaet an amino acid residue selected from the group consisting of lysine (K), arginine (R), alanine (A) and histidine (H) Hpredstavlyaet an amino acid residue selected from the group consisting of asparagine (N), glutamine (Q), serine (S), glycine (G) and alanine (A), preferably from asparagine (N), serine ( S), glycine (G) and alanine (A), an amino acid Hpredstavlyaet Remainder approx selected from the group consisting of glutamic acid (E), aspartic acid (D) and alanine (A), X b is an amino acid residue selected from the group consisting of glutamic acid (E) and aspartic acid (D), Hpredstavlyaet a amino acid residue selected from the group consisting of alanine (A) and tyrosine (Y), Hpredstavlyaet any amino acid residue, n and m, independently, is 0 or an integer greater than 0, and wherein the amino acid sequence according to formula I is not comprises identical or 7-me molecular weight polypeptide fragment of alpha-synuclein having the amino acid sequence KNEEGAP, wherein at least one said peptide or polypeptide has a binding capacity to an antibody which is specific to an epitope of alpha-synuclein comprising the amino acid sequence KNEEGAPdlya use in the prophylaxis and / or treatment synucleinopathies. 2. The composition of claim 1 wherein Hpredstavlyaet an amino acid residue selected from the group consisting of lysine (K) and arginine (R), and / or a Hpredstavlyaet Alapini (A) .3. The composition of
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充